Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression
Filip Liebsch(TH Köln - University of Applied Sciences), Gerhard Multhaup(McGill University), Philip Scheltens(Amsterdam Neuroscience), Luka Kulic(University of Zurich), Judes Poirier(McGill University), Wiesje M. van der Flier(University of Luxembourg), Paul Säftig(Christian-Albrechts-Universität zu Kiel), Adeola Shobo(McGill University), Vivienne Engelschalt(Freie Universität Berlin), Peter Kunach(Montreal Neurological Institute and Hospital), Irem Ulku(McGill University), John C.S. Breitner(McGill University), Charlotte E. Teunissen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Pedro Rosa‐Neto(Montreal Neurological Institute and Hospital), Mark A. Hancock(McGill University), Christoph Höck(Inserm), Randall J. Bateman(Washington University in St. Louis)
Cited by 62
Related Papers
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k